Streetbeat News

Revenues

BNTX

JNJ

MRNA

PFE

COVAX, the global initiative for equitable access to COVID-19 vaccines, will end on December 31, 2023, having delivered nearly 2 billion doses to 146 economies. The program, led by CEPI, Gavi, UNICEF, and WHO, is credited with preventing 2.7 million deaths. Gavi will continue vaccine support into 2024-2025. All COVAX supply agreements will conclude by end of 2023, except one extending into 2024 for routine immunization. The WHO has identified the JN.1 strain as a 'variant of interest' but considers it a low public health risk, with current vaccines effective against it.

Portfolio Pulse from Vandana Singh

December 20, 2023 | 3:54 pm

TNXP

Tonix Pharmaceuticals Holding Corp. (TNXP) has announced a registered direct offering with healthcare-focused institutional investors to raise up to $144 million. The deal includes $30 million in initial funding and up to $114 million from warrant exercises. The offering involves issuing shares and warrants, with Series C and D warrants exercisable at $0.555 and $0.85 per share, respectively. The proceeds will fund the new drug application for TNX-102 SL for fibromyalgia, working capital, and general corporate purposes. The offering is expected to close on December 22, 2023, with A.G.P./Alliance Global Partners as the placement agent.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 3:36 pm

SYRA

Syra Health Corp. (NASDAQ:SYRA) has announced the expansion of its healthcare workforce solutions, including training, a technology platform for job postings, and engagement services. The expansion aims to address the healthcare workforce shortage by offering development opportunities and a supportive workplace. The American Hospital Association's report highlights the ongoing workforce shortage, emphasizing the need for such services.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 3:34 pm

AAPL

NVDA

Jerome Powell's dovish speech suggests the Fed is done with interest rate hikes, indicating a pivot. The CPI is trending down, and retail sales are up, defying expectations for a weak Christmas season. Nvidia is moving production out of Taiwan to Vietnam, a strategic move to diversify its supply chain. Barron's calls for a higher neutral rate, aligning with DKI's views on future inflation and the impact of government spending.

Portfolio Pulse from Gary Brode

December 20, 2023 | 3:16 pm

BASFY

BFFAF

BASF SE (OTC:BFFAF) (OTC:BASFY) announced Dr. Markus Kamieth as the new Chairman of the Board of Executive Directors, effective April 25, 2024. He succeeds Dr. Martin Brudermüller. BASF is undergoing restructuring, including carving out divisions and reducing investments by €4 billion to address financial pressures and the German chemical industry's downturn. The industry is not expected to recover before 2025, with some companies permanently shutting down production.

Portfolio Pulse from Anusuya Lahiri

December 20, 2023 | 3:11 pm

SPY

USA existing home sales for November were reported at 3.82 million, surpassing the estimated 3.78 million and the prior month's 3.79 million. This indicates a slight improvement in the housing market.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 3:00 pm

SCS

During a conference call, Steelcase (SCS) reported that their teams are working diligently on cost reduction and are continuing to see benefits from pricing strategies. Additionally, the company has experienced an uptick in their win rate in Europe and Asia.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 2:56 pm

TRNO

Terreno Realty Corporation (NYSE:TRNO) sold an industrial property in West Caldwell, NJ for $17.8 million, which was originally purchased for $6.8 million in 2013. The property, a 93,000 square foot industrial distribution building, is fully leased to two tenants and generated an 11.2% internal rate of return for Terreno.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 2:15 pm

NRXS

NeurAxis, Inc. (NRXS) issued a shareholder letter highlighting progress since its IPO, including strong med-tech research publications, insurance policy coverage, and revenue growth in Massachusetts and Wisconsin. The company anticipates two new revenue opportunities in 2024: Functional Dyspepsia treatment and an exclusive license for a rectal expulsion device (RED) from the University of Michigan. Both have a $2B market opportunity. NeurAxis is preparing for FDA clearance submissions and expects to surpass 75M covered lives and significant revenue increases in 2024.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 2:11 pm

SCLX

Scilex Holding Company reported that ZTlido, its non-opioid pain treatment, is now the most prescribed by pain specialists, with a market share increase from 11.8% to 14.2% year-over-year in October. Year-to-date gross sales for ZTlido through November 2023 are estimated between $125.0 million to $135.0 million, a significant increase from $84.6 million in the same period of 2022. The projected full year gross sales for 2023 are expected to be between $140.0 million to $150.0 million, marking an estimated growth of 46% to 56% compared to $96.0 million in 2022.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 2:08 pm